FDA Finalizes Guidance for Developing Hepatitis C Antivirals

Clinical Trials Advisor
A A
The FDA finalized its guidance on developing direct-acting antivirals for chronic hepatitis C, outlining Phase III trial design options, enrollment criteria and safety evaluations for specific patient populations.

To View This Article:

Login

Subscribe To Clinical Trials Advisor